Actively Recruiting
A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Led by T.O.A.D. Oncology SA · Updated on 2026-03-16
180
Participants Needed
4
Research Sites
160 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with metastatic PSMA-expressing castration-resistant prostate cancer (CRPC).
CONDITIONS
Official Title
A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient must fully understand the study requirements and voluntarily sign informed consent.
- PSMA-expressing metastatic castration-resistant prostate cancer with documented progression based on serum PSA, RECIST 1.1 with PCWG3, and/or bone disease.
- At least one measurable metastatic lesion per RECIST 1.1.
- Adequate organ function.
- Prior orchiectomy and/or ongoing androgen deprivation therapy.
- Prior treatment with at least one androgen receptor pathway inhibitor (ARPI) drug.
You will not qualify if you...
- Previous treatment with strontium-89, samarium-153, rhenium-186, rhenium-188, radium-223, or hemi-body irradiation within 6 months before treatment.
- Systemic anticancer therapy including an investigational agent within 28 days before treatment.
- Known hypersensitivity to the components of TD001, its analogs, or excipients.
- Current dyspnea at rest, other disease requiring continuous oxygen therapy, or history of pneumonitis.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Yale University, Yale Cancer Center
New Haven, Connecticut, United States, 06520
Not Yet Recruiting
2
Institut Bergonié
Bordeaux, France, 33076
Actively Recruiting
3
Hôpital Paris Saint Joseph
Paris, France, 75014
Actively Recruiting
4
Institut Gustave Roussy
Villejuif, France, 94805
Actively Recruiting
Research Team
T
TOAD Clinical Operations
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here